MAZE - NASDAQ
Maze Therapeutics, Inc.
$25.40
+4.6%Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs includes MZE829, an oral small molecule inhibitor of apolipoprotein L1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor of the solute transporter SLC6A19, which is in phase I clinical trial for the treatment of chronic kidney disease. Maze Therapeutics, Inc. was formerly known as Modulus Therapeutics, Inc. and changed its name to Maze Therapeutics, Inc. in September 2018. The company was incorporated in 2017 and is based in South San Francisco, California.
At a Glance
Live Snapshotmaze
Cash at Beginning of Period
Last Annual Value
197.90M
3-Year CAGR
-1%
5-Year CAGR
%
10-Year CAGR
%
Maze Therapeutics, Inc. Competitors Analysis of Cash at Beginning of Period
| Company | Cash at Beginning of Period | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Maze Therapeutics, Inc. NASDAQ:MAZE | 197.90M | 25.1% | N/A | N/A | |
 Immunome, Inc. NASDAQ:IMNM | 143.45M | 91.5% | 29.2% | N/A | |
 Ardelyx, Inc. NASDAQ:ARDX | 64.93M | -12.3% | -6.5% | -4.9% | |
 Trevi Therapeutics, Inc. NASDAQ:TRVI | 34.10M | 39.4% | -5.4% | 12.1% | |
 Spyre Therapeutics, Inc. NASDAQ:SYRE | 89.42M | 34.9% | -0.6% | 11.8% | |
 Intellia Therapeutics, Inc. NASDAQ:NTLA | 240.35M | -23.4% | 7.9% | 12.2% | |
 BioCryst Pharmaceuticals, Inc. NASDAQ:BCRX | 104.92M | -30.0% | -17.5% | 13.8% | |
 Sionna Therapeutics, Inc. NASDAQ:SION | 38.75M | -11.4% | N/A | N/A |
Maze Therapeutics, Inc. Fair Value Envelope
Related Guides
Continue your MAZE research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.